Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alteogen Inc. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners. The prosecution activity spans 2 distinct art units, which indicates the focus within the company's biotechnology portfolio.
The busiest examiner for the company is FRONDA, CHRISTIAN L, who is handling 2 pending office actions. This examiner manages half of the company's workload, accounting for 2 of the 4 pending office actions. The remaining 2 pending office actions are split among the other 2 distinct examiners involved.
With the current volume of pending office actions in total, the company maintains an active presence in the Biotechnology & Pharmaceuticals sector. FRONDA, CHRISTIAN L is the primary point of contact, overseeing the workload across the 2 distinct art units. This concentration shows that half of the company's current patent applications are being reviewed by a single examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRONDA, CHRISTIAN L | 2 | 82.4% | +14.2% |
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
| JOHNSON, KARA D | 1 | 69.5% | +24.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17859466 | METHOD FOR PRODUCING FUSION PROTEIN HAVING IGG FC DOMAIN | JOHNSON, KARA D | 70d |
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17859466 | METHOD FOR PRODUCING FUSION PROTEIN HAVING IGG FC DOMAIN | JOHNSON, KARA D | 70d |
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — | §103DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — | §102§103§112DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | 1657 | §103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 17859466 | METHOD FOR PRODUCING FUSION PROTEIN HAVING IGG FC DOMAIN | JOHNSON, KARA D | 1632 | §103§112 | Final Rejection | 70d | Pending | Jul 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial